Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P14653
UPID:
HXB1_HUMAN
Alternative names:
Homeobox protein Hox-2I
Alternative UPACC:
P14653; Q4VB03
Background:
Homeobox protein Hox-B1, also known as Homeobox protein Hox-2I, plays a pivotal role in the developmental regulatory system, providing cells with specific positional identities along the anterior-posterior axis. It acts on anterior body structures, influencing their development.
Therapeutic significance:
Linked to Hereditary Congenital Facial Paresis 3, characterized by bilateral facial palsy and hearing loss, Homeobox protein Hox-B1's genetic variants suggest its potential as a target for therapeutic intervention in facial nerve dysfunction disorders.